Karyopharm Therapeutics (KPTI) Accumulated Depreciation & Amortization (2016 - 2025)
Karyopharm Therapeutics (KPTI) has disclosed Accumulated Depreciation & Amortization for 14 consecutive years, with $5.5 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Accumulated Depreciation & Amortization fell 17.65% year-over-year to $5.5 million, compared with a TTM value of $5.5 million through Dec 2025, down 17.65%, and an annual FY2025 reading of $5.5 million, down 17.65% over the prior year.
- Accumulated Depreciation & Amortization was $5.5 million for Q4 2025 at Karyopharm Therapeutics, down from $6.7 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $6.7 million in Q4 2024 and bottomed at $5.5 million in Q4 2025.
- Average Accumulated Depreciation & Amortization over 5 years is $6.3 million, with a median of $6.6 million recorded in 2023.
- The sharpest move saw Accumulated Depreciation & Amortization increased 16.75% in 2021, then fell 17.65% in 2025.
- Year by year, Accumulated Depreciation & Amortization stood at $6.1 million in 2021, then grew by 9.71% to $6.6 million in 2022, then fell by 1.2% to $6.6 million in 2023, then increased by 1.92% to $6.7 million in 2024, then dropped by 17.65% to $5.5 million in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for KPTI at $5.5 million in Q4 2025, $6.7 million in Q4 2024, and $6.6 million in Q4 2023.